Indeterminate Pulmonary Nodules Are Not Associated with Worse Overall Survival in Ewing Sarcoma
Overview
Affiliations
Aim: Lung metastases are a negative prognostic factor in Ewing sarcoma, however, the incidence and significance of sub-centimetre pulmonary nodules at diagnosis is unclear. The aims of this study were to (1): determine the incidence of indeterminate pulmonary nodules (IPNs) in patients diagnosed with Ewing sarcoma (2); establish the impact of IPNs on overall and metastasis-free survival and (3) identify patient, oncological and radiological factors that correlate with poorer prognosis in patients that present with IPNs on their staging chest CT.
Materials & Methods: Between 2008 and 2016, 173 patients with a first presentation of Ewing sarcoma of bone were retrospectively identified from an institutional database. Staging and follow-up chest CTs for all patients with IPN were reviewed by a senior radiologist. Clinical and radiologic course were examined to determine overall- and metastasis-free survival for IPN patients and to identify demographic, oncological or nodule-specific features that predict which IPN represent true lung metastases.
Results: Following radiologic re-review, IPN were found in 8.7% of patients. Overall survival for IPN patients was comparable to those with a normal staging chest CT (2-year overall survival of 73.3% [95% CI 43.6-89] and 89.4% [95% CI 81.6-94], respectively; p = 0.34) and was significantly better than for patients with clear metastases (46.0% [95% CI 31.9-59]; p < 0.0001). Similarly, there was no difference in metastasis-free survival between 'No Metastases' and 'IPN' patients (p = 0.16). Lung metastases developed in 40% of IPN patients at a median 9.6 months. Reduction of nodule size on neoadjuvant chemotherapy was associated with worse overall survival in IPN patients (p = 0.0084).
Conclusion: IPN are not uncommon in patients diagnosed with Ewing sarcoma. In this study, we were unable to detect a difference in overall- or metastasis-free survival between patients with IPN at diagnosis and patients with normal staging chest CTs.
UK guidelines for the management of bone sarcomas.
Gerrand C, Amary F, Anwar H, Brennan B, Dileo P, Kalkat M Br J Cancer. 2024; 132(1):32-48.
PMID: 39550489 PMC: 11723950. DOI: 10.1038/s41416-024-02868-4.
Hassan M, Ariyaratne S, Azzopardi C, Iyengar K, Davies A, Botchu R Br J Radiol. 2024; 97(1156):747-756.
PMID: 38346703 PMC: 11027319. DOI: 10.1093/bjr/tqae040.
Lloret I, Hompland I, Lobmaier I, Sundseth J, Server A Neuroradiol J. 2023; 37(5):640-644.
PMID: 37923348 PMC: 11456207. DOI: 10.1177/19714009231212358.
Brookes M, Chan C, Crowley T, Ragbir M, Beckingsale T, Ghosh K Cancers (Basel). 2023; 15(13).
PMID: 37444641 PMC: 10340540. DOI: 10.3390/cancers15133531.
Smolle M, Kogler A, Andreou D, Scheipl S, Bergovec M, Castellani C Cancers (Basel). 2023; 15(6).
PMID: 36980620 PMC: 10046382. DOI: 10.3390/cancers15061733.